AR122744A1 - COMPOUNDS AND METHODS FOR REDUCING THE EXPRESSION OF KCNT1 - Google Patents
COMPOUNDS AND METHODS FOR REDUCING THE EXPRESSION OF KCNT1Info
- Publication number
- AR122744A1 AR122744A1 ARP210101756A ARP210101756A AR122744A1 AR 122744 A1 AR122744 A1 AR 122744A1 AR P210101756 A ARP210101756 A AR P210101756A AR P210101756 A ARP210101756 A AR P210101756A AR 122744 A1 AR122744 A1 AR 122744A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- methods
- kcnt1
- reducing
- pharmaceutical compositions
- Prior art date
Links
Abstract
Se proporcionan compuestos, métodos y composiciones farmacéuticas para reducir la cantidad o actividad del ARN de KCNT1 en una célula o sujeto, y en determinadas circunstancias reducir la cantidad de proteína de KCNT1 en una célula o un sujeto. Estos compuestos, métodos y composiciones farmacéuticas son útiles para mejorar al menos un síntoma o característica de una afección neurológica. Dichos síntomas y características incluyen convulsiones, encefalopatía y anomalías del comportamiento. Los ejemplos no taxativos de afecciones neurológicas que se benefician de estos compuestos, métodos y composiciones farmacéuticas son la epilepsia de la infancia con crisis focales migratorias (EIMFS), la epilepsia del lóbulo frontal nocturna autosómica dominante (ADNFLE), el síndrome de West y el síndrome de Ohtahara.Compounds, methods, and pharmaceutical compositions are provided for reducing the amount or activity of KCNT1 RNA in a cell or subject, and in certain circumstances reducing the amount of KCNT1 protein in a cell or subject. These compounds, methods, and pharmaceutical compositions are useful for ameliorating at least one symptom or characteristic of a neurological condition. Such symptoms and features include seizures, encephalopathy, and behavioral abnormalities. Non-limiting examples of neurological conditions that benefit from these compounds, methods and pharmaceutical compositions are epilepsy of childhood with migratory focal seizures (EIMFS), autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE), West syndrome and Ohtahara syndrome.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044345P | 2020-06-25 | 2020-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122744A1 true AR122744A1 (en) | 2022-10-05 |
Family
ID=83835067
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101756A AR122744A1 (en) | 2020-06-25 | 2021-06-25 | COMPOUNDS AND METHODS FOR REDUCING THE EXPRESSION OF KCNT1 |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR122744A1 (en) |
-
2021
- 2021-06-25 AR ARP210101756A patent/AR122744A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002398A1 (en) | Compounds and methods for reducing the expression of kcnt1 | |
| RU2020119390A (en) | THE USE OF CANNABINOIDS IN THE TREATMENT OF SEX ASSOCIATED WITH LENNOX-GASTO SYNDROME | |
| BR112015014729A2 (en) | concave structure, harvester and processing method of an agricultural crop | |
| BR112019007383A2 (en) | compounds and methods for reducing atxn3 expression | |
| CO2020015256A2 (en) | Compounds and methods for reducing lrrk2 expression | |
| MA34020B1 (en) | PROCESS FOR TREATING FUNGAL INFECTIONS FUNGICIDAL COMPOSITIONS AND USE THEREOF | |
| AR047308A1 (en) | DIETARY SUPPLEMENT AND METHOD TO TREAT DISORDERS RELATED TO THE DIGESTIVE SYSTEM | |
| AR122744A1 (en) | COMPOUNDS AND METHODS FOR REDUCING THE EXPRESSION OF KCNT1 | |
| Koshal et al. | Effect of liraglutide on corneal kindling epilepsy induced depression and cognitive impairment in mice | |
| BR112012013034A2 (en) | methods and apparatus for particle segregation, including segregation and proliferation of fetal and stem cells | |
| CL2017001456A1 (en) | Seismic protection structure for partitions | |
| AR050346A1 (en) | THREAD DEVICE FOR HARVESTING MACHINES | |
| US20210379204A1 (en) | Method for calculating tolerance dose of human body to sugar alcohol and functional sugar | |
| UY39297A (en) | COMPOUNDS AND METHODS TO REDUCE THE EXPRESSION OF KCNT1 | |
| Armed Forces Health Surveillance Center (AFHSC | Erectile dysfunction among male active component service members, US Armed Forces, 2004-2013 | |
| CL2021002515A1 (en) | Compounds and methods for modulating ube3a-ats | |
| CU24418B1 (en) | A FOOD TAPE FOR A SUGAR CANE HARVEST | |
| BR112022016167A2 (en) | COMPOSITIONS AND METHODS TO TREAT AND PREVENT CONDITIONS ASSOCIATED WITH PREKALKREIN | |
| EA202192527A1 (en) | COMPOUNDS AND METHODS FOR REDUCING KCNT1 EXPRESSION | |
| Khan | N-nitro-L-arginine, a nitric oxide synthase inhibitor, aggravates iminodipropionitrile-induced neurobehavioral and vestibular toxicities in rats | |
| AR086738A1 (en) | USE OF AN ANTIBODY ANTI-CD20 OF GREAT CYTOTOXICITY FOR ANTIBODY DEPENDENT CELLULAR MEDIATION (ADCC) IN THE TREATMENT OF WALDENSTRÖM DISEASE | |
| AR118517A1 (en) | COMPOUNDS AND METHODS FOR MODULAR UBE3A-ATS | |
| Ravishanka et al. | Phenytoin/albendazole induced exanthematous eruptions: a case report. | |
| CL2019003662A1 (en) | Communication apparatus, method and computer program. | |
| PL415480A1 (en) | Construction of a cutter for harvesting energy crops |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |